Are we correctly using the inhibitors of gastric acid secretion and cytoprotective drugs? Results of a multicentre study

Ital J Gastroenterol Hepatol. 1997 Aug;29(4):325-9.

Abstract

Aim: To evaluate indications and frequency of prescriptions of pH-modifying and cytoprotective drugs in hospital departments.

Design of the study: Multicentre cohort transverse relevation.

Materials and methods: On a randomly selected day the clinical charts of 3685 inpatients were reviewed by a gastroenterologist and data were collected concerning the drug used, its dosage and indications for the prescription.

Results: 26.8% of hospitalized patients were under treatment on the day of the study. Ranitidine was the most frequently prescribed (73.9%). The purpose of treatment was cure of acute disease or symptoms in 27% of cases and prevention of peptic damage in 73%. Fear of development of stress mucosal lesions (28%) and therapy with other drugs (56%) motivated prophylactic treatment in the majority of cases. The examination of clinical charts failed to demonstrate any need for treatment in 51.4% of the patients. Disparities in the frequency of prescription between different departments and hospitals were found.

Conclusion: Criteria used for prescription of drugs for peptic diseases in hospitalized patients should be strictly monitored to avoid excessive and unmotivated use also in general practice.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Acute Disease
  • Anti-Ulcer Agents / therapeutic use*
  • Cohort Studies
  • Cytoprotection / drug effects*
  • Drug Prescriptions / statistics & numerical data
  • Drug Utilization / statistics & numerical data
  • Endoscopy, Digestive System
  • Gastric Acid / metabolism*
  • Histamine H2 Antagonists / therapeutic use
  • Humans
  • Middle Aged
  • Omeprazole / therapeutic use
  • Peptic Ulcer / metabolism
  • Peptic Ulcer / pathology
  • Peptic Ulcer / prevention & control*
  • Ranitidine / therapeutic use
  • Sucralfate / therapeutic use

Substances

  • Anti-Ulcer Agents
  • Histamine H2 Antagonists
  • Sucralfate
  • Ranitidine
  • Omeprazole